Compare KEP & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEP | ICLR |
|---|---|---|
| Founded | 1961 | 1990 |
| Country | South Korea | Ireland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 13.1B |
| IPO Year | 1996 | 2001 |
| Metric | KEP | ICLR |
|---|---|---|
| Price | $10.67 | $168.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $185.88 |
| AVG Volume (30 Days) | 742.1K | ★ 925.0K |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.43 | N/A |
| Revenue Next Year | $1.75 | $3.63 |
| P/E Ratio | ★ $4.54 | $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.58 | $66.57 |
| 52 Week High | $23.41 | $203.91 |
| Indicator | KEP | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 52.53 |
| Support Level | N/A | $162.32 |
| Resistance Level | $12.74 | $179.47 |
| Average True Range (ATR) | 0.16 | 6.91 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 8.23 | 54.55 |
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.